ABSTRACT - 597381 The present disclosure is directed to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of diabetes as well as an inflammatory disease such as rheumatoid arthritis, lupus, myasthenia gravis, muscular dystrophy, vasculitis, Chronic Obstructive Pulmonary Disease, inflammatory bowel disease, multiple schlerosis, acute allergic reactions, and transplant rejections, wherein: each of R1 and R4 is independently selected from H, halo, aliphatic, and alkoxy, wherein the aliphatic and alkoxy are optionally substituted with 1-3 of halo; R2 is halo, or hydroxy, and R'2 is H, or R2 and R'2 together form oxo; R3 is H; and Ring A is a phenyl, for use in the manufacture of a medicament for the treatment of diabetes, provided that the compound of formula (I) is not 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione.